{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4JThlYcLDA","founded_year":1863,"lastupdate":"2024-10-08T00:00:00.000Z","update_date":"2024-10-08T00:00:00.000Z","lastModified":"Oct 8, 2024","confidence_score":80,"active":1,"confidence_score_reason":"product stage, sector, business model, funding rounds, markets","urlname":"bayer","minimal_profile":null,"status":"Public","fullstatus":"Public on FWB on Oct, 1954;","acquired":0,"description_edited":0,"tag_line_edited":0,"phone":"+97297626700","registrar":"","biverification":"Jenny Sotnik-Talisman","recentupdates":[{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:38:49.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-08 13:28:46.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:03:17.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-12 10:35:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-08 13:45:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:35:53.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:10:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:02:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:11:35.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:23:34.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-12 10:36:39.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:23:34.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:18:10.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:02:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-08 13:28:46.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-07-03 10:01:32.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-10-24 06:38:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-10-24 06:38:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-10-24 06:38:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-10-21 07:54:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-10-21 07:31:34.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-10-21 07:57:07.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-10-21 07:57:09.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-10 10:41:40.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:34:12.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:34:12.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:34:12.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:35.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 05:28:20.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 13:16:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 08:02:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 14:27:54.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:33:37.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 06:45:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 06:47:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-10 10:41:41.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2019-06-10 07:25:53.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 13:14:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:23.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 06:14:20.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 06:14:20.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 06:14:20.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 06:14:20.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:54:03.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:54:03.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 05:34:25.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 13:10:50.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 06:23:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 06:43:12.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 05:58:56.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 13:43:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 13:16:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 13:16:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 11:55:16.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 12:39:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:56:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:56:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:56:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:57:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:57:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:57:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 12:31:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 12:31:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 05:43:11.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:33:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:34:20.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 05:37:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 11:02:01.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 11:02:01.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:33:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 06:39:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-05 06:11:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:37.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:37.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:37.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:37.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:37.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:58:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-10 10:41:40.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 13:17:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:33:23.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-06 13:09:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-06 13:09:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 05:53:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 14:22:51.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 13:19:02.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:46:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2019-06-10 08:31:04.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2019-06-10 08:31:04.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2019-06-10 08:31:04.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 12:45:11.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 14:22:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-05 06:13:40.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 06:42:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-10 10:40:30.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:55:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-10 10:40:08.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:33:20.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 06:07:44.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 06:30:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:34.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:33:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:33:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:33:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:33:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:33:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 12:53:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 12:53:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:35.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:49:34.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-05 05:38:11.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-05-30 08:48:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-05-30 08:48:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-05-30 08:48:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-05-30 08:48:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-05-30 08:48:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-05-30 08:48:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-05-30 08:48:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 12:39:54.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:45:26.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-10 07:12:11.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:57:45.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 10:57:45.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 05:53:03.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 14:23:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 05:42:54.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-02 13:11:12.000000","last_name":"Perlov","first_name":"Maor"},{"email":"danit.nitzan@bayer.com","source":"Manual","datetime":"2019-06-10 10:39:43.000000","last_name":"Nitzan","first_name":"Danit"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-05 05:45:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-06-03 10:36:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-08 13:28:46.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 06:11:54.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:36:47.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 15:00:01.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:11:43.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:02:42.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:02:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2024-10-08 13:28:46.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:02:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:11:43.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-08 13:41:50.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-22 14:02:43.000000","last_name":"Perlov","first_name":"Maor"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2019-06-10T00:00:00.000Z","crunchbaseid":"bayer-ag-germany","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Maor Perlov","creator_email":"maorperlov@gmail.com","createdate":"2019-05-30T00:00:00.000Z","lastupdatedate":"2024-10-08","hide_reason":null,"hide_reason_data":null,"logokey":"$twHLwv6Hwh7wKhGS9N2K7efDYY7UBJgTSuoNLBBW5HtT5AQgUK1OIZ","name":"Bayer","israeliacquisitions":0,"forbesranking":253,"investmentarm":null,"investmentarmname":null,"hubname":null,"acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":[],"alternativenames":[""],"country":"Germany","inisraelsince":"6/2008","inisraelsincemonth":"6","isisraeli":0,"marketcapital":43885748315,"marketcapitaldate":"2026-04-26T13:00:55.000Z","oneliner":"Pharmaceuticals","website":"https://www.bayer.com/","employees":"51-200","employees_exact":124,"employees_overall":"50,000+","employees_overall_exact":93471,"sociallinks":{"twitter":"https://twitter.com/bayer","youtube":"https://www.youtube.com/channel/UChXXF5KOk22Wc1OQ31yIn5Q","facebook":"https://www.facebook.com/bayer.israel","linkedin":"https://www.linkedin.com/company/1893","instagram":"https://www.instagram.com/bayeril"},"social":["https://www.linkedin.com/company/1893","https://www.instagram.com/bayeril","https://www.facebook.com/bayer.israel","https://twitter.com/bayer","https://www.youtube.com/channel/UChXXF5KOk22Wc1OQ31yIn5Q"],"flattenedsociallinks":"https://www.linkedin.com/company/1893|https://www.instagram.com/bayeril|https://www.facebook.com/bayer.israel|https://twitter.com/bayer|https://www.youtube.com/channel/UChXXF5KOk22Wc1OQ31yIn5Q","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Bayer AG is a global life science company with four main segments: pharmaceuticals, consumer health, crop science, and animal health.\n\nIn 2018, Bayer acquired Monsanto, including all of its operations in Israel and former subsidiaries. Bayer now operates in Israel through its fully owned subsidiary, Bayer Israel, which manages the pharmaceutical, consumer health, and crop science divisions. Additionally, Bayer runs an R&D site focused on vegetable seed breeding as part of its crop science division.\n\nSince 2022, Bayer has also been operating a Digital Hub in Israel, integrated into its global R&D network, which focuses on cybersecurity solutions. Furthermore, Bayer has partnered with the Israeli Innovation Authority to lead an International Climate Tech Program.\n\nBayer is actively scouting Israeli innovations in pharma, agriculture, and digital health technologies, and conducts numerous clinical trials in Israel.","founded":"5/1863","team":[{"name":"Roni Levi","email":"roni.levi@bayer.com","phone":"","gender":"Male","userid":"nrGabHbiS9r1eIJvjjqybPWlaN9ioyoOkrcdLJ6cmBjEtCyIvpq4X0","bounced":false,"claimed":null,"founder":0,"urlname":"roni-levi-1","visible":1,"memberid":"kq7tdgU4aWsw46HG6Vmqc5KJMv6LtV7SGYMFpTVjWMxFKpTD7JpUbc","position":"CEO, Bayer Israel","last_name":"Levi","claimtoken":null,"first_name":"Roni","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"RL","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yael Mor","email":"yael.mor@bayer.com","phone":"","gender":"female","userid":"nPCQVFPZTcfEybLjoIgzqkwDEKodfnSbXWBC82eEHH7Zb8EqmGeWqt","bounced":false,"claimed":null,"founder":0,"urlname":"yael-mor","visible":1,"memberid":"ytNEeiyxqiWSeDxMmE90sxaHXy0HUEUl92WoHEiv4b1hHZxmswR8uE","position":"Head of Cyber Security - Israel","last_name":"Mor","claimtoken":null,"first_name":"Yael","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yael-mor-00801056/","unsubscribed":true,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"YM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Sharon  Arad-Tzuk ","email":"","phone":"","gender":"Female","userid":"xw6JiaxYFplzrZr28G7oyLP41CUnaHSpelckDDYYRnaI29FasyheTj","bounced":false,"claimed":null,"founder":0,"urlname":"sharon-arad-tzuk-1","visible":1,"memberid":"AGm0qNkeMTpfoLFKzhOAB7tOtlCzcVvikMjGD9vfFgMLnuvI72Xf9I","position":"Head of HR Bayer Israel","last_name":" Arad-Tzuk ","claimtoken":null,"first_name":"Sharon","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/sharon-arad-tzuk-24a056b1/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"S ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[{"name":"Agamon","hidden":false,"raised":"$8.47M","founded":"2018","fullurl":"/company_page/agamon","logokey":"$7M0OOCwfMpUZVNSfruG43DFjXS0tJCWvSvIJ6tFwYH4acyBQWRGjeO","urlname":"agamon","employees":"11-50","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoPGVz-kJDA","description":"Patient Management Platform","fundingstage":"Seed","businessmodel":"B2B","raisedNumber":8475000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$7M0OOCwfMpUZVNSfruG43DFjXS0tJCWvSvIJ6tFwYH4acyBQWRGjeO","style":"","hiddenCompanyTooltip":""},{"name":"AgroGreen","hidden":false,"raised":"Undisclosed","founded":"1999","fullurl":"/company_page/agrogreen","logokey":"$bWjcTTw9mIRm3YRCWtnrppiYD2q2tJBhDWd8nzitKvIiL8L6L0SJor","urlname":"agrogreen","employees":"11-50","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPu2m8cKDA","description":"Biological Pesticides and Nematicides Using Microorganisms","fundingstage":"Acquired","businessmodel":"B2B","raisedNumber":0,"logourl":"https://storage.googleapis.com/clean-finder-353810/$bWjcTTw9mIRm3YRCWtnrppiYD2q2tJBhDWd8nzitKvIiL8L6L0SJor","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[{"id":"b197e261-00d0-4c0e-82e4-1b8245346d37","timestamp":"2019-06-10 10:40:30.000000","resources_type":1,"resources_title":"","resources_file_name":"$v2LPiUHRwZSYMOw6by1XyG6KdLk7MoA3nwBydSLt6XARI8jFSjZSCf","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$v2LPiUHRwZSYMOw6by1XyG6KdLk7MoA3nwBydSLt6XARI8jFSjZSCf","url":"https://storage.googleapis.com/clean-finder-353810/$v2LPiUHRwZSYMOw6by1XyG6KdLk7MoA3nwBydSLt6XARI8jFSjZSCf"},{"id":"47b84120-a831-40a5-a633-4c4f592a03aa","timestamp":"2019-06-10 10:40:08.000000","resources_type":1,"resources_title":"","resources_file_name":"$2yeK5kx4vRcSe4xgFl9a7QjoIXKABmx7tsiSFaITldsf4Nstf17hno","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$2yeK5kx4vRcSe4xgFl9a7QjoIXKABmx7tsiSFaITldsf4Nstf17hno","url":"https://storage.googleapis.com/clean-finder-353810/$2yeK5kx4vRcSe4xgFl9a7QjoIXKABmx7tsiSFaITldsf4Nstf17hno"},{"id":"9a32e783-735f-42ee-8781-3386fec9ad9f","timestamp":"2019-06-10 10:39:43.000000","resources_type":1,"resources_title":"","resources_file_name":"$0EACA2Pi9FIBwwC23yE89WWWDIzG2lRKAsULEovU7H6IAejsLye991","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$0EACA2Pi9FIBwwC23yE89WWWDIzG2lRKAsULEovU7H6IAejsLye991","url":"https://storage.googleapis.com/clean-finder-353810/$0EACA2Pi9FIBwwC23yE89WWWDIzG2lRKAsULEovU7H6IAejsLye991"},{"id":"510b94c1-5ac0-41b4-b14f-fc11633aa34e","timestamp":"2019-06-05 05:49:23.000000","resources_type":1,"resources_title":"","resources_file_name":"$iuRvBNrrQM0CQTUiuagK2gkgbuodI8HCNYlLLEwuLbk4x6RilQe1Um","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$iuRvBNrrQM0CQTUiuagK2gkgbuodI8HCNYlLLEwuLbk4x6RilQe1Um","url":"https://storage.googleapis.com/clean-finder-353810/$iuRvBNrrQM0CQTUiuagK2gkgbuodI8HCNYlLLEwuLbk4x6RilQe1Um"}],"affiliatedOrganizations":null,"address":{"israeli":[{"id":"1611df1a-770c-4026-9cef-90e60eb3bcb9","city":"Hod HaSharon","type":["R&D "," Sales ","Innovation Center"],"address":"HaHarash Street 36, Hod Hasharon, Israel","placeid":null,"notactive":0,"openeddate":"2018-01-08","registrarid":"514081256","firstrdcenter":0,"registrarname":"Bayer Israel Ltd"},{"id":"65067b67-806a-402b-8ff7-44b613094e91","city":"Misgav","type":["R&D"],"address":"Misgav, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":"511782526","firstrdcenter":0,"registrarname":"A.B. Seeds Ltd"}],"officesabroad":[{"id":"YAMQBIkWfsuTRLdeqt8XWQ348MqqJsWZnh8bBa1CJKkEeQ3pVwNmcs","city":"Leverkusen","address":"Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, Germany","country":"Germany","placeid":null}]},"headquarter_address":"Kaiser-Wilhelm-Allee 1, Leverkusen, Germany","news":[{"id":"UMfWXUWC158H6KLYolXsxqMz62VzF5PIdpMmMkoePOcJkXzG407X83","date":"Apr 28, 2026","link":"https://finance.yahoo.com/sectors/healthcare/articles/dermal-mycosis-market-research-report-080500792.html","source":"finance.yahoo.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"Mu8IF8sXoSxQh9Lmlqzk2pt0gf3flE9WVf0HhyRgFZkMEZyZLktRsr","news_summary":"Dermal Mycosis Market Research Report 2025-2026 & 2035, Competitive Analysis of Bayer, Kenvue, Karo Healthcare, Novartis, Glenmark Pharmaceuticals, Sun Pharma, Teva, and Sandoz","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"CkNHjYh7gEcqqJq4IF7uUhIYjZna1lwM8hllT6PcWNfxEKaROu7tdy","date":"Apr 23, 2026","link":"https://finance.yahoo.com/sectors/healthcare/articles/dermatomycoses-market-report-2025-2035-085700195.html","source":"finance.yahoo.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"olte8CnASXaOCPwXr4hHYlF8QGLFl4XXy321Psa397hLK4PvvAI4dB","news_summary":"Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"r3GNRR1JnCkXfSkWfGR7kjypwQlFyNCkSmGo3ehAQ0w7XklxMVBaj4","date":"Mar 11, 2026","link":"https://finance.yahoo.com/news/nurexone-announces-corporate-updates-122800116.html","source":"finance.yahoo.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"8rinbOGniexW9KZZULKJqF3MZQz9mBHXXJQUwqZFzjK045nXa1UbVU","news_summary":"NurExone Announces Corporate Updates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"AFNIWaYdV8K5dttIlBsodSKqPn0jtuUFnUi3J3NYUJkXWagExHoOnl","date":"Feb 25, 2026","link":"https://finance.yahoo.com/news/guidde-raises-50m-train-humans-150000674.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"AI adoption","round":"Series B","company":"Guidde","layoffs":null,"summary":"Guidde, an AI digital adoption platform, has announced a $50 million Series B funding round led by PSG Equity, with participation from monday.com and other investors. The company has grown to over 4,500 customers, including major enterprises like Anheuser-Busch and Bayer, and has achieved 3x annual revenue growth for three consecutive years. Guiddes platform helps organizations create video-based documentation for software applications, enabling employees to learn workflows efficiently. The investment will accelerate the deployment of their platform, which is designed to train both human employees and AI agents. Guiddes approach addresses the challenges of AI adoption in enterprises by providing real-time, application-specific training data.","partners":["monday.com"],"customers":["Anheuser-Busch","Bayer","Nasdaq","Yahoo","SentinelOne"],"eventType":null,"investors":["PSG Equity","monday.com","Norwest","Entrée Capital","Qualcomm Ventures","Inkberry Ventures"],"confidence":10,"key_topics":["AI tools","workflows","training","investment","documentation"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$50 million","structured_issues":["Investment","Customers"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":"developing","structuredIssuesShow":"#Investment  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"COtbAvVsXtPTY2kFif1J5Oai2z2psPh2t93SUoIft8zMguYlUGViD3","news_summary":"Guidde Raises $50M to Train Humans on AI and AI on Humans","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"iS50bmZqryr9FwDxbnWtW2gxVshCzy9KVVR3neoserjk0x02rM8uJW","date":"Jan 21, 2026","link":"https://finance.yahoo.com/news/j-j-stock-down-despite-152800664.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings","round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson reported strong fourth-quarter 2025 earnings, with earnings per share of $2.46, surpassing the Zacks Consensus Estimate of $2.43. The companys sales reached $24.56 billion, exceeding expectations and reflecting a 9.1% increase from the previous year. The growth was driven by the Innovative Medicines segment, which saw a 10% rise in sales, bolstered by strong performance from key products like Darzalex, Tremfya, and Erleada. Despite competitive pressures affecting some products like Imbruvica, the overall performance was robust, with new drugs contributing significantly to growth. The positive earnings and sales figures indicate a growth-positive impact for the company.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["earnings","sales","growth","drugs","competition"],"date_of_event":"Q4 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CNzZohzjndFuXqJ7Z8GvbcRZyqbTpNSGmZlRiQ6kHUvMdMjS6XRrTM","news_summary":"J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"epBmYWXGinoirfnm4Vn1RNIe100WAbqJNErC6UAhhNNlAdf1avgFr6","date":"Jan 11, 2026","link":"https://www.globes.co.il/news/article.aspx?did=1001531627","source":"www.globes.co.il","visible":1,"analysis":{"tags":"investment","round":null,"company":"KAHR","layoffs":null,"summary":"KAHR, a portfolio company of Hadasit Bio, announced positive results from its Phase IIa clinical trial for its colorectal cancer treatment, which showed improved survival rates. The company also raised $22 million to complete a Phase IIb trial, with interim results expected by the end of the year and final results in 2027. The funding round was led by Flerie, Peregrine, Oriella, aMoon, and Cancer Focus, with additional credit from SPRIM Global Investments. This investment will support further development and testing of KAHRs cancer treatment.","partners":null,"customers":null,"eventType":null,"investors":["Flerie","Peregrine","Oriella","aMoon","Cancer Focus","SPRIM Global Investments"],"confidence":9,"key_topics":["investment","clinical trial","cancer treatment","immunotherapy","survival rates"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"22 million","structured_issues":["Investment","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Investment  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oLMcbAkzujQ6UHoHIU0iYHuhMMGXWNa4bUxpJ2epjtDfNzchf5dWQ0","news_summary":"OpenAI תשיק גרסה ייעודית של ChatGPT למענה על שאלות רפואיות. המחיר: ויתור על הפרטיות ● חוקרים מאוניברסיטת סטנפורד מראים שלילה אחד של שינה יכול לנבא עשרות מחלות ברמות דיוק של 80% ומעלה ● באייר מקימה בישראל מעבדה שתדמה מתקפות סייבר על מפעלי תרופות, וחברות ישראליות מציגות פריצות דרך – מטיפול ואבחון סרטן ועד \"אינקובטור חיבוק\" לפגים ● השבוע בביומד","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"wCr4Vpl9BX4hSNAvw7NpPtNbKLNnf4y6WdV6nbuV8zi52U0Q4Jno1u","date":"Dec 8, 2025","link":"https://finance.yahoo.com/news/galmed-announces-acceptance-breaking-abstract-133000981.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Galmed Pharmaceuticals Ltd.","layoffs":null,"summary":"Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, announced the presentation of a late-breaking abstract for its lead drug candidate, Aramchol, at the HEP-DART 2025 Meeting. The abstract highlights the potential of Aramchol to enhance the activity of regorafenib, a standard care drug, in treating hepatocellular carcinoma (HCC) and other gastrointestinal (GI) cancers. This has led to the initiation of a Phase 1/2 clinical trial by VCU Massey Comprehensive Cancer Center, with enrollment starting in 2026. The trial aims to evaluate the efficacy of combining Aramchol with regorafenib and Metformin. Positive results could accelerate Aramchols clinical development and expand Galmeds oncology pipeline.","partners":"VCU Massey Comprehensive Cancer Center","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["SCD1","Aramchol","regorafenib","clinical trial","oncology"],"date_of_event":"December 9, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ThuhYhfhXO9aFrZ79bRW2ySS8JQr98ZmnNTSTTFecpeFIfT9DAkCS5","news_summary":"Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7vTki84VMPOKj0Wl04Igxl2A3JbN6681QnpkPWolhK7JYk6z00hl5A","date":"Nov 17, 2025","link":"https://finance.yahoo.com/news/galmed-announces-top-line-results-133000201.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Galmed Pharmaceuticals Ltd.","layoffs":null,"summary":"Galmed Pharmaceuticals Ltd. announced promising results from a study evaluating the synergistic effects of Aramchol in combination with Bayers cancer drug, Stivarga® (regorafenib), and Metformin. The study suggests potential for a new fixed-dose combination treatment for gastrointestinal cancers, which could serve as a life-cycle IP strategy for Stivarga® as its patents near expiration. The combination is expected to enter Phase 1b clinical trials in early 2026. The collaboration with Virginia Commonwealth University aims to overcome drug resistance in GI cancers. Positive findings could accelerate Aramchols clinical development and expand Galmeds pipeline, creating value for investors.","partners":"Virginia Commonwealth University","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["cancer","drug resistance","clinical trials","patent strategy","synergistic effect"],"date_of_event":"May 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1DgAeVvways8ecHxdqU9XXN6HDDt8CJlJ8n1vtr2hM9A2bQ6gJG6hI","news_summary":"Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"EBb89Ge0J3Q9tlUeWGoFIgCNltaxw860rLAV7BqvRxUFZnSppv5aCP","date":"Oct 14, 2025","link":"https://finance.yahoo.com/news/jnj-beats-q3-earnings-ups-160000522.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings, sales","round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson reported strong third-quarter 2025 earnings, with earnings per share of $2.80, surpassing the Zacks Consensus Estimate of $2.77. This marks a 15.7% increase from the previous year. The companys sales reached $24.0 billion, exceeding expectations and reflecting a 6.8% rise from the prior year. The growth was driven by increased sales in the Innovative Medicines segment, particularly from key products like Darzalex, Tremfya, and Erleada. Despite some challenges from generic competition affecting drugs like Imbruvica, the overall performance was robust. The companys international sales also showed significant growth, contributing to the positive outlook.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["earnings","sales","growth","competition","drugs"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Z6dcLDotl9Y888E002ek6NqSzRYUnttHVUXTFH06QnHzCwHAPCpiEh","news_summary":"JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9UBQpMzPprLv0JmocCTqehKFd4haHMo4piu9bGP616tosrpPxl26kQ","date":"Aug 1, 2025","link":"https://uk.finance.yahoo.com/news/bp-diageo-disney-uber-wpp-stocks-watch-153517077.html","source":"uk.finance.yahoo.com","visible":1,"analysis":{"tags":"earnings","round":null,"company":"BP","layoffs":null,"summary":"BP is set to release its second-quarter results amid declining oil and gas prices, with analysts expecting earnings of $1.35 per share and $60 billion in revenue. The company is under pressure due to weak cash flow, rising net debt, and challenges in its transition to cleaner energy sources. Activist investor Elliott has raised concerns over BPs performance, particularly its lagging shareholder returns. Analysts predict a pre-tax profit of $4.6 billion, up from $4.2 billion in Q1, but still below past levels. BPs cash flow and net debt, forecasted to be $24.9 billion by Q1 2025, remain key issues.","partners":null,"customers":null,"eventType":null,"investors":"Elliott","confidence":9,"key_topics":["earnings","oil prices","renewable transition","cash flow","debt"],"date_of_event":"1 Aug 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"Uc0OWxxloZA043AS6y6I3YCqlLx35U0Rl1ekRWwAjk85Xhz6BOQLVK","news_summary":"Stocks to watch next week: BP, Diageo, Disney, Uber and WPP","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"bEV7ic1HQOvAbwlaoluH0p2mq7JYNbo7EJaS9HXHXFwlcbqakBqxMw","date":"Jul 31, 2025","link":"https://finance.yahoo.com/news/multiple-sclerosis-clinical-trials-market-094300493.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","round":null,"company":"ResearchAndMarkets.com","layoffs":null,"summary":"The article discusses the addition of the Multiple Sclerosis - Global Clinical Trials Review, 2025 report to ResearchAndMarkets.coms offerings. This report provides a comprehensive overview of the global landscape of clinical trials for Multiple Sclerosis, including data by region, phase, and sponsor. It highlights top drugs and trial trends, aiding in strategic decision-making and competitive advantage. The report is generated using a proprietary database and includes data from over 80 clinical trial registries and other sources. It aims to assist in formulating business strategies, identifying key locations for trials, and understanding global market opportunities.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Multiple Sclerosis","Clinical Trials","Global Overview","Trial Trends","Decision-Making"],"date_of_event":"July 31, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8agDAawsHJY5Hbzt6qA5Xi5m0QSEJWJ7vTgNWTrhXbpQDtFGrUvkgc","news_summary":"Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GEUP8uTmyFx5H17wvt6YEqmevvZ1l7ipE3ZgEXglgMGV8fcKYH01Yh","date":"Jul 3, 2025","link":"https://finance.yahoo.com/news/agricultural-biotechnology-market-outlook-report-152200850.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"innovation","round":null,"company":"Agricultural Biotechnology Market","layoffs":null,"summary":"The agricultural biotechnology market is experiencing significant growth, driven by advancements in gene editing, precision breeding, and AI integration. The market expanded from USD 58.47 billion in 2024 to USD 65.60 billion in 2025 and is projected to reach USD 113.24 billion by 2030, with a CAGR of 11.64%. This growth is fueled by the demand for climate-resilient and sustainable solutions, as well as regional innovation and strategic alliances. The market encompasses various crop types, trait types, and application areas, with leading companies like Bayer, Corteva, and Syngenta playing key roles. The focus on food security and regulatory progress further supports this upward trajectory.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["gene editing","precision breeding","AI integration","sustainability","regulatory shifts"],"date_of_event":"July 03, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"x1kwYp8NG9fXDaKYbRlAR9jGzs7tWXcmSqDXoQf8tj622dLdYl45dv","news_summary":"Agricultural Biotechnology Market Outlook Report to 2030, with Profiles of Bayer, Corteva, Syngenta, BASF, FMC, Bioceres Crop Solutions, Evogene, Marrone Bio Innovations, Calyxt & Arcadia Biosciences","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"u6Af6kJ89o0kuRJMF3L07qme7GMrYcw1rcAIYG5qq7VhsQJ7t6ptzN","date":"Jun 17, 2025","link":"https://finance.yahoo.com/news/teva-partners-fosun-develop-tev-160200038.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"Teva Pharmaceutical","layoffs":null,"summary":"Teva Pharmaceutical has entered into a strategic collaboration with Fosun Pharmaceutical to co-develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. This partnership grants Fosun exclusive rights to develop, manufacture, and commercialize the therapy in China and select regions, while Teva retains rights elsewhere. The collaboration aims to leverage Fosuns oncology expertise and Tevas innovative drug development to broaden access to this novel cancer therapy. TEV-56278 is in early-stage studies for various cancers, including melanoma. No financial details were disclosed. Despite a 22.9% decline in Tevas shares year-to-date, the partnership is seen as a strategic move to enhance market presence and therapeutic reach.","partners":"Fosun Pharmaceutical","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["collaboration","oncology","immunotherapy","cancer","market"],"date_of_event":null,"product_stage":"early-stage","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"I8dv8vooC9DGbyyYlBShBSeofejvF8gkYFOZomt86vm8xgNlqEb0wj","news_summary":"Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MH5VYN0CEys8tx9RhUatk8h6RuUpC4HvDwQ9tHPK1N5OxbDlN28o1o","date":"Feb 4, 2025","link":"https://www.prnewswire.com/il/news-releases/redhill-announces-initiation-of-phase-2-study-of-opaganib-and-darolutamide-in-advanced-prostate-cancer-302367315.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"RedHill Biopharma Ltd.","layoffs":null,"summary":"RedHill Biopharma Ltd. has initiated a Phase 2 clinical trial to evaluate the efficacy of opaganib in combination with Bayers darolutamide for treating metastatic castrate-resistant prostate cancer (mCRPC). The study, financially supported by Bayer and the Ramsay Hospital Research Foundation, aims to test the potential of opaganib to enhance the effectiveness of standard androgen receptor pathway inhibition treatments. The trial will involve 80 patients and utilize a lipid biomarker test to select candidates with poor prognosis. The primary endpoint is improved 12-month radiographic progression-free survival. This development represents a significant step for RedHill in addressing treatment-resistant prostate cancer, a market valued at $12 billion.","partners":["Bayer","Ramsay Hospital Research Foundation","Chris OBrien Lifehouse","ANZUP"],"customers":null,"eventType":null,"investors":["Bayer","Ramsay Hospital Research Foundation"],"confidence":9,"key_topics":["prostate cancer","clinical trial","drug combination","biomarker test","cancer treatment"],"date_of_event":"October 2023","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qcaLPYumn3TQvBco0vCELm1v2zwaCM2Hhxe7T9p0FzcnfA13QCav0j","news_summary":"The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ebwDbZOCPIke6cgge3uxk47UoSiggTkJ5Rl3ifVvxXTXeMQEjiU6dl","date":"Feb 22, 2024","link":"https://www.croplife.com/crop-inputs/bayer-agplenus-team-up-to-develop-a-new-sustainable-weed-control-solution-using-ai-technology/","source":"www.croplife.com","visible":1,"analysis":{"tags":"Partnership, AI Technology, Crop Protection","company":"AgPlenus Ltd.","layoffs":"Not mentioned","summary":"AgPlenus Ltd., a subsidiary of Evogene Ltd., has signed a licensing and collaboration agreement with Bayer AG. The partnership will leverage AgPlenus AI-driven computational modelling technology to design and optimize molecules for broad-spectrum herbicidal activity. The herbicide market, valued at $42.81 billion in 2024, is crucial for global food security and regenerative agricultural practices. The collaboration aims to address the growing challenge of weed resistance to existing products, exacerbated by climate change. Bayer will have exclusive rights to develop and commercialize products from the collaboration, while AgPlenus will receive an upfront payment, ongoing research funding, milestone payments, and royalties.","partners":"Bayer AG","customers":"Farmers","investors":"Bayer AG","confidence":9,"key_topics":["Collaboration","AI Technology","Crop Protection","Herbicide","Sustainability"],"date_of_event":"Not mentioned","valuation_amount":"Herbicide market is valued at $42.81 billion in 2024","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"rMLd9X1OXoG4yrP5v08reozq3qG6PdSXom8BNtOAhj5RUWRaoxsCKH","news_summary":"Bayer, AgPlenus Team Up to Develop a New Sustainable Weed Control Solution Using AI Technology","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"86e9df89-f890-46dc-9ac3-66d1dd0a5d23","date":"Jul 1, 2022","link":"https://www.timesofisrael.com/pharma-giant-bayer-to-set-up-cybersecurity-center-in-israel/","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":"cybersecurity","company":"Bayer","layoffs":null,"summary":"Pharmaceutical giant Bayer will open a cybersecurity development center in Israel to engage and partner with the strong Israeli tech ecosystem. The center will operate in Bayer Israels existing offices and collaborate with Israeli cybersecurity startups and companies. This move is seen as a growth-positive development for Bayer, as it allows the company to integrate with Israels cybersecurity ecosystem and provide added value for both Bayer and the Israeli market. Biotech and pharmaceutical companies are highly susceptible to cyberattacks, making cybersecurity a crucial focus for Bayer. The company has been active in Israel since 2008 and has made investments in various Israeli startups in the pharmaceutical and agricultural tech sectors.","partners":["Mastercard","Fujitsu","Anheuser-Busch InBev (AB InBev)","PricewaterhouseCoopers"],"customers":null,"investors":null,"confidence":9,"key_topics":["Cybersecurity","Israel","Bayer","Partnerships","Pharmaceuticals"],"date_of_event":"June 29, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SaIyo0rQy8yN363afnnM3QUiWWmyH3K50CiQ2c8fUTUIVx8mNgv7Ra","news_summary":"Pharma giant Bayer to set up cybersecurity center in Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"FX20awSqqw6i9FUNt5l4Omod9tpnSDlOM1WGWAbQrwK80X57cvux8X","date":"Jun 29, 2021","link":"https://www.jpost.com/health-science/bayer-to-test-new-drugs-on-3d-printed-heart-tissue-at-tel-aviv-university-633162","source":"www.jpost.com","visible":1,"analysis":{"tags":"collaboration, drug testing","company":"Ramot","layoffs":null,"summary":"Ramot, the technology transfer company of Tel Aviv University, has signed a collaboration with Bayer to test new drugs on 3D-printed heart tissues. This new method of testing bypasses traditional screening methods, making it faster, cheaper, and more efficient. The collaboration aims to develop and validate a platform for in vitro cardiotoxicity screening using 3D-printed human heart tissue. Ramot has licensed the technology to a spin-off company called Matricelf, which focuses on engineering personalized spinal-cord implants. Researchers estimate that within 10-15 years, it will be possible to print personalized organs and tissues, eliminating the need for organ donations and the risk of transplant rejection.","partners":["Bayer"],"customers":null,"investors":null,"confidence":9,"key_topics":["3D-printed heart tissues","drug testing","collaboration","efficiency","personalized organs"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"O1Kc0z5OljECkoi9aTFhCuaXuBJToUMv6WC8gZ5nWjkWyRFysMAiGz","news_summary":"https://www.jpost.com/health-science/bayer-to-test-new-drugs-on-3d-printed-heart-tissue-at-tel-aviv-university-633162","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c9b80b4b-e956-4662-9ffa-5f5b7fefd6c4","date":"Feb 9, 2021","link":"https://www.timesofisrael.com/pharma-giant-bayer-scouts-israeli-startup-scene-in-search-of-competitive-edge/","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":["pharmaceuticals","startups","partnerships","digital health","investment"],"company":"Bayer AG","layoffs":null,"summary":"The article discusses how global pharmaceutical giants, including Bayer AG, are partnering with startups and utilizing the latest technologies to stay competitive. Bayer has been actively investing in Israeli startups in the fields of pharma, agriculture, and digital health. They have invested in companies like Ukko, Evogene, Compugen, Netafim, and collaborated with Prospera Technologies. Bayer is also exploring collaborations with Israeli universities and focusing on digital health technologies. The company recently signed a collaboration agreement with CureVac NV for the development of a COVID-19 vaccine. The article highlights the importance of partnerships and external innovation for the pharmaceutical industry.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["pharmaceutical industry","startups","collaboration","digital health","investment"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JNJWtUXaraopUoeYrRpTij6VhFMQKqZW3MEjc6vsDealCVb2tUNrTE","news_summary":"Pharma giant Bayer scouts Israeli startup scene in search of competitive edge","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"opNDLur6QzAYLjwV5Xa9B2GQHnfkfy41ZpKSHV6EYRSkiqowgdpRhR","date":"Jan 27, 2021","link":"https://en.globes.co.il/en/article-Bayer-leads-40m-investment-in-Israeli-biotech-co-Ukko-1001358705","source":"en.globes.co.il","visible":1,"analysis":{"tags":"biotech, food allergies, sensitivities, funding","company":"Ukko","layoffs":null,"summary":"Israeli biotech company Ukko has completed a $40 million Series B financing round led by Bayers impact investment arm Leaps. The funding will allow Ukko to begin clinical trials for its peanut allergy therapy and develop its celiac and gluten sensitivity treatment. Ukko uses artificial intelligence and protein engineering to develop healthier food and therapies for food allergies. The company has already built a large molecular map of food allergies and has generated promising data suggesting that its investigational peanut and gluten proteins do not trigger allergic reactions. Ukko aims to redefine healthy food at the molecular level and has plans to address additional major food allergens in the future.","partners":null,"customers":null,"investors":["Bayers impact investment arm Leaps","Continental Grain Company","PeakBridge Ventures","Skyviews Life Science","Fall Line Capital","Khosla Ventures","Innovation Endeavors","TIME Ventures"],"confidence":9,"key_topics":["Food allergies","Sensitivities","Clinical trials","Protein engineering","Artificial intelligence"],"date_of_event":"January 27, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$40 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9TxjFajX4CZQqeZPhB8vVnabiB29t7mO7ZcaDrNQVpysoQLYmfPDkM","news_summary":"Bayer leads $40m investment in Israeli biotech co Ukko","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"lbzWBc3BfzTFKuHb34BJ8HHONgVL9YkLdnsZQbECj1vgPSoNnyhiH5","date":"Jul 28, 2020","link":"https://www.israelhayom.com/2020/07/28/bayers-leaps-to-invest-in-israeli-biotech-incubator-futurx/","source":"www.israelhayom.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"MEDoPiIsWv1bEhtsYakpE42l4xu6CBkIjiexg7jT6y4tJV0T1QHKy3","news_summary":"https://www.israelhayom.com/2020/07/28/bayers-leaps-to-invest-in-israeli-biotech-incubator-futurx/","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"e2599fcd-ce59-46a9-bbe2-71ae8cee995e","date":"Feb 7, 2019","link":"https://nocamels.com/2019/02/bayer-netafim-bgn-research-drip-irrigation/","source":"nocamels.com","visible":1,"analysis":{"tags":"research collaboration","company":"Bayer","layoffs":null,"summary":"Bayer, Netafim, and BGN Technologies have announced a three-year research collaboration to optimize drip irrigation using digital tools. The collaboration aims to develop Bayer and Netafims DripByDrip solution, which uses Netafims drip irrigation systems to deliver Bayers crop protection products. The research will be conducted in Israel at the Jacob Blaustein Institutes for Desert Research of BGU and Netafim facilities. The collaboration highlights the leading position of BGU in the field of agriculture and its focus on solutions for extreme desert and drylands conditions. The integration of digital tools for drip irrigation optimization is expected to contribute to sustainable agriculture.","partners":["Netafim","BGN Technologies"],"customers":null,"investors":null,"confidence":8,"key_topics":["research collaboration","drip irrigation","digital tools","crop protection","agriculture"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0rtnFkysyj7qGtYYhZ9Ca17t5f3Y9OIZ2qkqXf09LK3Q3Vc3TutPx0","news_summary":"Netafim, BGU, Bayer To Collaborate On Drip Irrigation Systems","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":null,"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCUiMPrCgw","hub":null,"date":"1954-10-01","batch":"","token":"","amount":null,"hub_id":null,"source":"https://www.investor.bayer.de/en/stock/stock-history/","ticker":"BAYN","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"FWB","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD04NPOCQw","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$FOHEXYOagmmcYPOeLnIUnn72vv64MGnXct8WTB8wIuj7ypubMzxHMk","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$FOHEXYOagmmcYPOeLnIUnn72vv64MGnXct8WTB8wIuj7ypubMzxHMk","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""}],"techcommunityinvolvement":null,"tags":["cyber-security","digital-healthcare","precision-agriculture","foodtech","agtech","pharma-companies","seeds","smart-farming","crops","pharmaceuticals","clinical-trials","healthcare","life-sciences","innovation-center"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"50,000+","fundingtype":"Multinational","parsedName":"Bayer","logourl":"https://storage.googleapis.com/clean-finder-353810/$twHLwv6Hwh7wKhGS9N2K7efDYY7UBJgTSuoNLBBW5HtT5AQgUK1OIZ","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$twHLwv6Hwh7wKhGS9N2K7efDYY7UBJgTSuoNLBBW5HtT5AQgUK1OIZ","teamMembersNumber":3,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}